Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Idrugs : the Investigational Drugs Journal
|
July 4, 2003
New targets and innovative strategies in cancer treatment: a short course for clinicians. 7-8 February 2003, Monte Carlo, Monaco
Ferry Eskens
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]
|
March 28, 2003
Critical assessment of angiogenesis inhibitors in clinical trials
Ferry Eskens
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2008
The multi-institutional phase I study: disadvantages without advantages?
Jaap Verweij, Ferry Eskens, Maja de Jonge
Molecular Oncology
|
March 6, 2012
Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design
Jaap Verweij, Maja de Jonge, Ferry Eskens, et al.
Targeted Oncology
|
October 27, 2020
Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
Ramesh K Ramanathan, Daniel D Von Hoff, Ferry Eskens, et al.
Targeted Oncology
|
April 22, 2020
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
Ramesh K Ramanathan, Daniel D Von Hoff, Ferry Eskens, et al.
Investigational New Drugs
|
March 22, 2014
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
Jordi Rodon, Irene Braña, Lillian L Siu, et al.
British Journal of Cancer
|
December 14, 2021
First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours
Debbie Robbrecht, Christiane Jungels, Morten Mau Sorensen, et al.
Investigational New Drugs
|
July 31, 2019
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
W Larry Gluck, Mrinal M Gounder, Richard Frank, et al.
Molecular Cancer Therapeutics
|
June 11, 2009
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors
Richard D Baird, Jos Kitzen, Paul A Clarke, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Idrugs : the Investigational Drugs Journal
|
July 4, 2003
New targets and innovative strategies in cancer treatment: a short course for clinicians. 7-8 February 2003, Monte Carlo, Monaco
Ferry Eskens
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]
|
March 28, 2003
Critical assessment of angiogenesis inhibitors in clinical trials
Ferry Eskens
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2008
The multi-institutional phase I study: disadvantages without advantages?
Jaap Verweij, Ferry Eskens, Maja de Jonge
Molecular Oncology
|
March 6, 2012
Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design
Jaap Verweij, Maja de Jonge, Ferry Eskens, et al.
Targeted Oncology
|
October 27, 2020
Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
Ramesh K Ramanathan, Daniel D Von Hoff, Ferry Eskens, et al.
Targeted Oncology
|
April 22, 2020
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
Ramesh K Ramanathan, Daniel D Von Hoff, Ferry Eskens, et al.
Investigational New Drugs
|
March 22, 2014
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
Jordi Rodon, Irene Braña, Lillian L Siu, et al.
British Journal of Cancer
|
December 14, 2021
First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours
Debbie Robbrecht, Christiane Jungels, Morten Mau Sorensen, et al.
Investigational New Drugs
|
July 31, 2019
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
W Larry Gluck, Mrinal M Gounder, Richard Frank, et al.
Molecular Cancer Therapeutics
|
June 11, 2009
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors
Richard D Baird, Jos Kitzen, Paul A Clarke, et al.
Page
of 2